Regarding irAE enterocolitis due to ICI administration, the frequency of enteritis complications has been reported at 18%–23% when anti‐CTLA‐4 antibodies and anti‐PD‐1 inhibitors are used in combination [10]; this tends to be higher than when antibodies are used alone. This evidence concerns the gene CTLA4 and enteritis.